Physician profile
Christopher Adubor
NPI 1962464594
$12,198.25
in general payments reported to CMS, 2019-2025
27 companies · $2,498 in 2025
The $2,498 reported for 2025 was more than what 91% of Nephrology (Internal Medicine) providers received nationally (typical 2025 total: $311).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $2,828 · 2020: $621 · 2021: $1,530 · 2022: $1,586 · 2023: $2,112 · 2024: $1,023 · 2025: $2,498.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $5,614 · Education: $18.85.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $5,613.84 |
| Education | $18.85 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novo Nordisk INC | $5,493.92 | 2019-2025 | Ozempic, Wegovy, Rybelsus |
| Boehringer Ingelheim Pharmaceuticals, INC. | $1,129.32 | 2019-2025 | Jardiance |
| Astrazeneca Pharmaceuticals LP | $1,129.16 | 2019-2025 | Farxiga, Fasenra |
| Bayer Healthcare Pharmaceuticals INC. | $794.57 | 2021-2025 | |
| Novartis Pharmaceuticals Corporation | $443.07 | 2019-2024 | |
| Lilly USA, LLC | $390.81 | 2022-2025 | Kisunla, Mounjaro, Jardiance |
| Abbott Laboratories | $264.34 | 2024-2025 | Freestyle Libre 3, Freestyle Libre |
| Amgen INC. | $248.26 | 2023-2025 | Repatha, Otezla, Repatha |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $236.55 | 2019 | |
| Mallinckrodt Hospital Products INC. | $210.26 | 2021-2023 | Acthar |
| Akebia Therapeutics INC | $207.27 | 2019-2021 | |
| Glaxosmithkline, LLC. | $185.68 | 2021-2024 | Arexvy, Trelegy Ellipta, Shingrix |
| Mannkind Corporation | $183.54 | 2020-2023 | Afrezza |
| Merck Sharp & Dohme LLC | $182.50 | 2022-2024 | Verquvo |
| Scpharmaceuticals INC. | $169.52 | 2025 |
Show all 27 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Otsuka America Pharmaceutical, INC. | $155.82 | 2021-2023 | Jynarque |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $153.12 | 2025 | Caplyta |
| Allergan, INC. | $124.98 | 2020 | |
| Janssen Pharmaceuticals, INC | $124.54 | 2022 | |
| Idorsia Pharmaceuticals US INC | $122.91 | 2023 | Quviviq |
| Abbvie INC. | $71.29 | 2021-2025 | |
| Vifor Pharma, INC. | $56.13 | 2023-2025 | Veltassa, Korsuva |
| Dexcom, INC. | $49.70 | 2021-2025 | Dexcom G6 Transmitter |
| Ironwood Pharmaceuticals, INC | $22.59 | 2022 | |
| Shield Therapeutics INC | $21.28 | 2023 | Accrufer |
| Sanofi-Aventis U.S. LLC | $16.27 | 2019 | |
| Amarin Pharma, INC. | $10.85 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Christopher Adubor listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.